Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

• Status: Active, not recruiting
• Trial end date: 2021-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, randomized, double-blind, placebo-controlled phase 2 study in subjects 8 years of age and older who present with verruca vulgaris (common warts) and desire treatment. Subjects may have up to a total of 6 common warts located on their trunk or extremities that will be treated with study medication and followed throughout the study protocol therapy. All warts will be treated two times per day (BID) for12 weeks. Approximately 90 subjects will be enrolled in this study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Veloce BioPharma LLC
• Treatments: Cadexomer iodine; Iodine; Povidone; Povidone-Iodine

Criteria

Inclusion Criteria:

• Subject is able to comprehend and is willing to sign an informed consent/assent for participation in this study.

• Male or female ≥ 8 years old.

• Subject has a clinical diagnosis of verruca vulgaris (common warts).

• Subject has up to 6 warts located on the trunk or extremities

Exclusion Criteria:

• Subject has clinically atypical warts on the trunk or extremities.

• Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.)

• Subject has periungual, subungual, genital, anal, mosaic, plantar, flat, or filiform wart identified as a wart for study treatment.